These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34542933)

  • 21. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
    Goel B; Bhardwaj N; Tripathi N; Jain SK
    Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
    Khazir J; Maqbool T; Mir BA
    Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Broad-spectrum Respiratory Virus Entry Inhibitors.
    Zhao H; Yuen KY
    Adv Exp Med Biol; 2022; 1366():137-153. PubMed ID: 35412139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive review on the antiviral activities of chalcones.
    Elkhalifa D; Al-Hashimi I; Al Moustafa AE; Khalil A
    J Drug Target; 2021 Apr; 29(4):403-419. PubMed ID: 33232192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential inhibitors of SARS-CoV-2: recent advances.
    Jamalipour Soufi G; Iravani S
    J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
    Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
    Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NAD+-consuming enzymes in immune defense against viral infection.
    Shang J; Smith MR; Anmangandla A; Lin H
    Biochem J; 2021 Dec; 478(23):4071-4092. PubMed ID: 34871367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
    Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
    Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic potential of resveratrol against emerging respiratory viral infections.
    Filardo S; Di Pietro M; Mastromarino P; Sessa R
    Pharmacol Ther; 2020 Oct; 214():107613. PubMed ID: 32562826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses.
    Karam BS; Morris RS; Bramante CT; Puskarich M; Zolfaghari EJ; Lotfi-Emran S; Ingraham NE; Charles A; Odde DJ; Tignanelli CJ
    J Med Virol; 2021 Apr; 93(4):1843-1846. PubMed ID: 33314219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antivirals and antiviral strategies.
    De Clercq E
    Nat Rev Microbiol; 2004 Sep; 2(9):704-20. PubMed ID: 15372081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptides to combat viral infectious diseases.
    Al-Azzam S; Ding Y; Liu J; Pandya P; Ting JP; Afshar S
    Peptides; 2020 Dec; 134():170402. PubMed ID: 32889022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2.
    Tonk M; Růžek D; Vilcinskas A
    Viruses; 2021 May; 13(5):. PubMed ID: 34069206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When cyclin-dependent kinases meet viral infections, including SARS-CoV-2.
    Yan Y; Tang YD; Zheng C
    J Med Virol; 2022 Jul; 94(7):2962-2968. PubMed ID: 35288942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two years into COVID-19 - Lessons in SARS-CoV-2 and a perspective from papers in FEBS Letters.
    Greber UF
    FEBS Lett; 2021 Dec; 595(23):2847-2853. PubMed ID: 34787897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Broad-spectrum coronavirus antiviral drug discovery.
    Totura AL; Bavari S
    Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.